One of the major obstacles to the efficacy of cancer therapy is the tumor microenvironment that often outgrows its blood supply and harbors hypoxic regions that are resistant to chemo- and radiotherapy. TRAIL is part of the host immune system that suppresses cancer and its metastases and both TRAIL as well as TRAIL receptor agonist antibodies are currently in early phase clinical trial testing. In preliminary studies we have uncovered evidence that certain tumor cells, including p53-null human HCT116 colon tumor cells that are sensitive to TRAIL under normoxic conditions, become significantly resistant to TRAIL under severely hypoxic conditions. Such tumor cells are not effectively sensitized to TRAIL under hypoxia by combination therapies that include TRAIL plus 5- Fluorouracil, TRAIL plus irinotecan, or TRAIL plus the hypoxia sensitizer Tirapazamine. This prompted us to develop and carry out a high throughput chemical library screen that has identified a number of small molecules, including a family of structurally-related nucleoside analogues we refer to as the SLMs. SLMs are potent sensitizers of TRAIL under hypoxia and some family members have cytotoxic effects as single agents under hypoxia. In vivo studies reveal anti-tumor effects of novel small molecules combined with TRAIL and novel non-invasive whole animal optical imaging reveals that such combinations are associated with reduced levels of hypoxia within treated tumors as well as reduced vascularity. These are exciting findings that merit further investigation through the following approaches:
Specific Aim #1 : Investigate mechanisms of resistance to TRAIL therapy under hypoxia with specific focus on c-Myc, Mcl-1, HIF and NFkB signaling pathways.
Specific Aim #2 : Investigate mechanisms of sensitization to TRAIL under hypoxia by novel small molecules, SLMs, isolated from high throughput chemical library screening.
Specific Aim #3 : Investigate the impact of the tumor microenvironment on TRAIL plus SLM sensitivity through non-invasive in vivo imaging of tumor hypoxia and anti-tumor effects. This proposal is highly relevant to the understanding of the barriers to effective anti-cancer therapy and has broad applicability to other systems and therapies as we gain this understanding. The proposal has high translational relevance as we are developing novel therapeutic combinations that may be tested in the clinic.

Public Health Relevance

Hypoxia within the tumor microenvironment is a major obstacle to successful cancer therapy and needs to be investigated for progress to be made in therapeutic development. This proposal has developed methods for targeting sensitization to the biologic therapy TRAIL in the hypoxic microenvironment. We have identified novel effective sensitizers that have anti-tumor effects, whereas chemotherapy or Tirapazamine failed to sensitize significantly. The progress of this work is likely to have impact on the development of novel therapeutic approaches that have high potential for clinical translation.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Ogunbiyi, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Pennsylvania State University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Crowder, Roslyn N; Dicker, David T; El-Deiry, Wafik S (2016) The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death. J Biol Chem 291:5960-70
Prabhu, Varun V; Allen, Joshua E; Dicker, David T et al. (2015) Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. Cancer Res 75:1423-32
Allen, Joshua E; Krigsfeld, Gabriel; Mayes, Patrick A et al. (2013) Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 5:171ra17
Warfel, Noel A; Dolloff, Nathan G; Dicker, David T et al. (2013) CDK1 stabilizes HIF-1? via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle 12:3689-701
Dolloff, Nathan G; Allen, Joshua E; Dicker, David T et al. (2012) Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther 11:2321-30
Prabhu, Varun V; Allen, Joshua E; Hong, Bo et al. (2012) Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opin Ther Targets 16:1161-74
Mayes, Patrick A; Dolloff, Nathan G; Daniel, Colin J et al. (2011) Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3? and CDK1. Cancer Res 71:5265-75
Hart, Lori S; Dolloff, Nathan G; Dicker, David T et al. (2011) Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle 10:2331-8
Dolloff, Nathan G; Mayes, Patrick A; Hart, Lori S et al. (2011) Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med 3:86ra50
Allen, Joshua E; El-Deiry, Wafik S (2010) Circulating Tumor Cells and Colorectal Cancer. Curr Colorectal Cancer Rep 6:212-220

Showing the most recent 10 out of 14 publications